Carvykti achieves multiple myeloma landmark

Johnson & Johnson (NYSE: JNJ) has announced long-term results from the Phase III CARTITUDE-4 study showing that a single infusion of Carvykti (ciltacabtagene autoleucel; cilta-cel) significantly extended overall survival (OS) in those with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI).

Carvykti reduced the risk of death by 45% versus standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd).

With these data, Carvykti is now the first cell therapy to improve OS versus standard therapies for patients with lenalidomide-refractory multiple myeloma as early as second line.